Compare Stocks: IMRN, ATYR, CELU, and EDSA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.38 -1.3%	$0.50	$0.38 ▼ $1.12	$38.18M	0.53	713,152 shs	942,418 shs
CELU Celularity	$1.29 +4.0%	$1.00	$0.56 ▼ $2.55	$35.89M	0.79	12.25 million shs	180,906 shs
EDSA Edesa Biotech	$3.87 -6.1%	$5.27	$0.72 ▼ $20.32	$39.72M	1.05	84,880 shs	94,356 shs
IMRN Immuron	$1.19 -4.0%	$1.21	$0.68 ▼ $2.39	$10.01M	1.16	6.49 million shs	148,926 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-1.31%	-16.50%	-25.98%	-14.74%	-64.44%
CELU Celularity	+4.03%	-10.42%	+85.34%	+71.47%	-40.00%
EDSA Edesa Biotech	-6.07%	-18.01%	-31.50%	-47.35%	+57.32%
IMRN Immuron	-4.03%	-32.39%	+10.19%	+12.26%	-35.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$0.38 -1.3%	$0.50	$0.38 ▼ $1.12	$38.18M	0.53	713,152 shs	942,418 shs
CELU Celularity	$1.29 +4.0%	$1.00	$0.56 ▼ $2.55	$35.89M	0.79	12.25 million shs	180,906 shs
EDSA Edesa Biotech	$3.87 -6.1%	$5.27	$0.72 ▼ $20.32	$39.72M	1.05	84,880 shs	94,356 shs
IMRN Immuron	$1.19 -4.0%	$1.21	$0.68 ▼ $2.39	$10.01M	1.16	6.49 million shs	148,926 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	-1.31%	-16.50%	-25.98%	-14.74%	-64.44%
CELU Celularity	+4.03%	-10.42%	+85.34%	+71.47%	-40.00%
EDSA Edesa Biotech	-6.07%	-18.01%	-31.50%	-47.35%	+57.32%
IMRN Immuron	-4.03%	-32.39%	+10.19%	+12.26%	-35.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	2.67	Moderate Buy	N/A	N/A
CELU Celularity	1.00	Sell	N/A	N/A
EDSA Edesa Biotech	2.67	Moderate Buy	$5.00	29.20% Upside
IMRN Immuron	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest IMRN, ATYR, CELU, and EDSA Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/27/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/5/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	CELU Celularity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/29/2026	EDSA Edesa Biotech	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
6/26/2026	ATYR aTyr Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	EDSA Edesa Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	IMRN Immuron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$190K	198.30	N/A	N/A	$0.69 per share	0.56
CELU Celularity	$26.55M	1.41	N/A	N/A	($1.32) per share	-0.98
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	$0.45 per share	N/A
IMRN Immuron	$5.47M	1.76	N/A	N/A	$0.93 per share	1.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$74.12M	-$0.62	N/A	N/A	N/A	N/A	-95.89%	-69.67%	11/5/2026 (Estimated)
CELU Celularity	-$91.72M	-$3.33	N/A	N/A	N/A	-345.45%	N/A	-77.94%	11/13/2026 (Estimated)
EDSA Edesa Biotech	-$7.19M	-$1.69	N/A	N/A	N/A	N/A	-560.22%	-105.74%	N/A
IMRN Immuron	-$2.61M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IMRN, ATYR, CELU, and EDSA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q4 2026	IMRN Immuron	N/A	-$0.09	N/A	-$0.0850	N/A	$1.27 million
8/13/2026	Q3 2026	EDSA Edesa Biotech	-$0.4350	-$0.60	-$0.1650	-$0.60	N/A	N/A
8/7/2026	Q2 2026	ATYR aTyr Pharma	-$0.1214	-$0.11	+$0.0114	-$0.11	N/A	$189.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
CELU Celularity	N/A	N/A	N/A	N/A	N/A
EDSA Edesa Biotech	N/A	N/A	N/A	N/A	N/A
IMRN Immuron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	N/A	5.12	5.12
CELU Celularity	N/A	0.15	0.15
EDSA Edesa Biotech	N/A	2.76	2.76
IMRN Immuron	N/A	7.17	5.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
CELU Celularity	19.02%
EDSA Edesa Biotech	5.50%
IMRN Immuron	0.12%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	5.75%
CELU Celularity	17.30%
EDSA Edesa Biotech	24.40%
IMRN Immuron	7.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	98.09 million	92.45 million	Optionable
CELU Celularity	220	28.95 million	23.94 million	Optionable
EDSA Edesa Biotech	20	9.64 million	7.29 million	Not Optionable
IMRN Immuron	N/A	8.07 million	7.51 million	Not Optionable

IMRN, ATYR, CELU, and EDSA Headlines

Recent News About These Companies

Immuron Ltd ADR IMRN

September 9, 2026 | morningstar.comM

3 Penny Stocks to Watch Today, September 8

September 8, 2026 | tipranks.com

Immuron Signs Exclusive US Distribution Deal for Digestive-Health Product PROIBS

September 4, 2026 | finance.yahoo.com

Immuron Stock Surges 56% On U.S. Distribution Deal For PROIBS

September 4, 2026 | rttnews.com

IMRN stock skyrockets 60%, heads for best day in over 2 years – what’s driving the super rally today?

September 4, 2026 | msn.com

Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results

September 4, 2026 | benzinga.com

Immuron surges after U.S. PROIBS launch deal adds to recent strong FY26 update

September 4, 2026 | quiverquant.comQ

Immuron Stock Surges Friday: What's Driving the Action?

September 4, 2026 | benzinga.com

Immuron To Launch PROIBS In U.S. After Australia Debut; Pre-market Shares Up

September 4, 2026 | rttnews.com

Immuron Limited Signs Exclusive U.S. Distribution Agreement for PROIBS with Calmino Group AB

September 4, 2026 | quiverquant.comQ

Immuron to launch PROIBS® in the United States

September 4, 2026 | globenewswire.com

Immuron FY26 Revenue Rises 6% As Net Loss Narrows And Cash Surges

August 28, 2026 | rttnews.com

Immuron Reports FY26 Preliminary Results

August 28, 2026 | markets.businessinsider.com

Immuron Limited Reports Record FY26 Sales, Improved Profit and Key Pipeline Milestones

August 28, 2026 | quiverquant.comQ

Immuron Issues FY26 Preliminary Results With Safe Harbor Caution

August 27, 2026 | tipranks.com

Immuron Narrows Loss as Travelan Sales Lift Revenue and Cash Reserves

August 27, 2026 | tipranks.com

Immuron CEO to Spotlight Oral Immunotherapy Portfolio at Emerging Growth Conference

August 18, 2026 | tipranks.com

Immuron CEO Showcases Gut-Targeted Antibody Platform at TechKnow Invest Roadshow

July 26, 2026 | tipranks.com

Immuron CEO to Present TechKnow Invest Roadshow in Melbourne

July 21, 2026 | tipranks.com

Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

July 20, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN, ATYR, CELU, and EDSA Company Descriptions

aTyr Pharma NASDAQ:ATYR

$0.38 -0.01 (-1.31%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+1.54%)

As of 09/16/2026 07:50 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Celularity NASDAQ:CELU

$1.29 +0.05 (+4.03%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.29 +0.00 (+0.16%)

As of 09/16/2026 07:54 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Edesa Biotech NASDAQ:EDSA

$3.87 -0.25 (-6.07%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$3.94 +0.06 (+1.68%)

As of 09/16/2026 07:36 PM Eastern

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Immuron NASDAQ:IMRN

$1.19 -0.05 (-4.03%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$1.17 -0.02 (-1.76%)

As of 09/16/2026 07:54 PM Eastern

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMRN, ATYR, CELU, and EDSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMRN, ATYR, CELU, and EDSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMRN, ATYR, CELU, and EDSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN, ATYR, CELU, and EDSA Company Descriptions

aTyr Pharma NASDAQ:ATYR

Celularity NASDAQ:CELU

Edesa Biotech NASDAQ:EDSA

Immuron NASDAQ:IMRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IMRN, ATYR, CELU, and EDSA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IMRN, ATYR, CELU, and EDSA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IMRN, ATYR, CELU, and EDSA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN, ATYR, CELU, and EDSA Company Descriptions

aTyr Pharma NASDAQ:ATYR

Celularity NASDAQ:CELU

Edesa Biotech NASDAQ:EDSA

Immuron NASDAQ:IMRN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools